



### SUGGESTED FORMULA

Tranexamic Acid 250 mg Capsule Size #0 Sustained Release

Version number: 1.0

Volume or quantity: 100 capsules

---

Tranexamic Acid, EP (T1370)	25gm
Hypromellose 2910, 4,000 cps, USP (H1128)	17.5gm
Size 0, locking capsules	100

---

### SUGGESTED COMPOUNDING PROCEDURES

Weigh all ingredients

1. Geometrically triturate powders together until uniformly mixed avoiding heat of friction
2. Mix powders per pharmacy SOPs – (e.g. geometric dilution, blade, v-blend, RAM™)
3. Fill capsules in vented enclosure (hood)
4. Cap and “snap” each bottom into its lid.
5. Weigh sample capsules to check variability and standard deviation per pharmacy SOPs
6. Bottle and label with prescription label and appropriate auxiliary labels.
7. Suggested Quality assessments
  - a. % variability & % deviation from theoretical <10% - (remake if >10%)
  - b. Capsule size
  - c. Capsule color
  - d. Quantity
  - e. Label - auxiliary labels, storage, BUD, compounded medication

Store in air-tight container, at **Controlled room temperature**

No claims are made as to the safety or efficacy of this preparation. This formulation is provided solely at the unsolicited request of the pharmacist.

Beyond-Use Dates of preparations are conservative estimates from reference books, peer-reviewed literature, and intended duration of therapy, formulation from commercially available products, organoleptic observations and current USP guidelines. Compounders may have stability studies performed by a reputable laboratory if they wish to extend the Beyond-Use Date. It is recommended that you follow USP <795> recommendations for potency testing.

Beyond-Use Date should be based on the current issue of the USP <795> - six months

Precautions should be taken to prevent cross-contamination and exposure of ingredients to the compounder and contamination of the preparation by the compounder. Wear appropriate protective equipment. Use safety enclosures (hoods) when weighing and mixing.

5/18 JD